Phase 2 Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who can read and speak English, so they are able to give written consent and complete questionnaires
- People who are willing to sign and date a consent form agreeing to take part
- People who are willing and able to follow all study procedures for the full duration of the trial
- People who are able to swallow tablets or capsules and are willing to follow the study medication schedule
- People who have been diagnosed with rheumatoid arthritis (RA) by a doctor, confirmed through their medical records
- People who are currently taking both oral prednisone AND one other FDA-approved medicine for RA (from a specific list of approved medicines), with no changes to that treatment in the past 90 days
- People enrolling in the 15-day taper group must currently be taking 7.5mg of prednisone per day
- People enrolling in the 150-day taper group must currently be taking 5mg of prednisone per day
Who may not be able to join:
- People who have used steroid medicines (taken by mouth, injection into a vein, or injection into a muscle) for more than 2 weeks in the past year for a reason other than RA
- People whose RA is assessed as more than moderately active, based on a standard disease activity score or a specialist doctor's assessment
- People who have been diagnosed by a doctor with a condition where their adrenal glands do not produce enough hormones (primary or secondary adrenal insufficiency)
- People who have taken part in another clinical trial or received an experimental treatment within the past 90 days
- People who are pregnant
- People who have certain medical or mental health conditions that study staff determine would prevent safe or full participation in the trial — examples given include schizophrenia, active cancer, psychosis, thoughts of suicide, or a history of substance abuse (note: stable anxiety or depression are listed as not being exclusions)
- People who currently use, have recently used (within the past 6 months), or regularly use artificial nails or nail enhancements, as these can affect how certain measurements are taken during the study
- People who have any other condition, situation, or circumstance that study staff determine would prevent them from completing the study as planned (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Beth Wallace, MD MSc, VA Ann Arbor Healthcare System, Ann Arbor, MI
Phone: (734) 548-2987
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with subjective taper intolerance; Number of participants with objective taper intolerance; Net glucocorticoid dose reduction
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.